Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
- PMID: 18695943
- DOI: 10.1007/s11239-008-0264-4
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI). We hypothesized that treatment with NSAIDs prior to an index MI would be associated with an increase in the risk of death, heart failure and recurrent MI among patients with ST-segment elevation MI (STEMI) treated with fibrinolytic therapy.
Methods: In ExTRACT-TIMI 25, patients with STEMI were treated with aspirin and fibrinolytic therapy and randomized to either enoxaparin or unfractionated heparin. We included patients who had received NSAIDs within 7 days of enrollment and evaluated the incidence of MI, the composite of death and MI and the composite of death, MI, severe heart failure and shock through 30 days.
Results: Of 20,479 patients enrolled, 572 (2.8%) received an NSAID within 7 days of enrollment. NSAID treatment prior to entry was associated with a higher incidence of 30-day death or nonfatal recurrent MI (15.9% vs. 10.8%, univariate P < 0.001). In multivariable models adjusting for randomization group and differences in baseline characteristics, NSAID use was associated with higher odds of MI (adjusted odds ratio [OR(adj)] 1.44, 95% confidence interval [CI] 1.01-2.07, P = 0.047), the composite of death and MI (OR(adj) 1.29, 95% CI 1.00-1.66, P = 0.051), and the composite of death, MI, severe heart failure and shock (OR(adj) 1.29, 95% CI 1.02-1.65, P = 0.037).
Conclusions: Among STEMI patients treated with a fibrinolytic agent and aspirin, use of NSAIDs in the week preceding the incident event was associated with a higher incidence of MI, the composite of death and MI as well as the composite of death, MI, severe heart failure and shock at 30 days.
Similar articles
-
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.Am Heart J. 2007 Dec;154(6):1078-84, 1084.e1. doi: 10.1016/j.ahj.2007.07.027. Am Heart J. 2007. PMID: 18035078 Clinical Trial.
-
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.J Thromb Thrombolysis. 2009 Jan;27(1):1-10. doi: 10.1007/s11239-008-0284-0. Epub 2008 Oct 19. J Thromb Thrombolysis. 2009. PMID: 18931978
-
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.J Am Coll Cardiol. 2007 Jun 12;49(23):2256-63. doi: 10.1016/j.jacc.2007.01.092. Epub 2007 May 25. J Am Coll Cardiol. 2007. PMID: 17560290 Clinical Trial.
-
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.JAMA. 2004 Jul 7;292(1):89-96. doi: 10.1001/jama.292.1.89. JAMA. 2004. PMID: 15238596 Review.
-
Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials.Clin Cardiol. 2009 Jul;32(7):358-64. doi: 10.1002/clc.20432. Clin Cardiol. 2009. PMID: 19609890 Free PMC article. Review.
Cited by
-
Acute coronary syndromes: diagnosis and management, part I.Mayo Clin Proc. 2009 Oct;84(10):917-38. doi: 10.4065/84.10.917. Mayo Clin Proc. 2009. PMID: 19797781 Free PMC article. Review.
-
Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model.Molecules. 2019 Jan 12;24(2):270. doi: 10.3390/molecules24020270. Molecules. 2019. PMID: 30642049 Free PMC article.
-
Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.Br J Clin Pharmacol. 2010 Jun;69(6):689-700. doi: 10.1111/j.1365-2125.2010.03627.x. Br J Clin Pharmacol. 2010. PMID: 20565461 Free PMC article.
-
Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders.Biology (Basel). 2018 Nov 16;7(4):49. doi: 10.3390/biology7040049. Biology (Basel). 2018. PMID: 30453474 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical